Successful Completion of TRANSFORM II Enrollment
Primary Investigator, Dr. Bernardo Cortese, has announced the successful completion of patient enrollment in the transformative TRANSFORM II randomized controlled trial (RCT). This landmark study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels.
About the TRANSFORM II Trial
TRANSFORM II is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare, now achieving an impressive target enrollment of over 1,820 patients. The final patient was enrolled recently, marking a significant milestone for this comprehensive study. Led by Study Chairman Prof. Bernardo Cortese from a prestigious heart and vascular institute, and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloons and has enrolled patients from 52 centers across various regions, including Europe, Asia, and South America.
Key Features of the Trial
Some highlights of the TRANSFORM II trial include:
- Comparative Arms: A head-to-head evaluation of MagicTouch SCB versus Everolimus-Eluting Stent (EES)
- Patient Population: Involving 1,832 patients with de-novo lesions in coronary arteries.
- Primary Endpoint: An assessment of Target Lesion Failure at 12 months following a non-inferiority design.
- Follow-Up: Participants will be monitored for up to 60 months (5 years) to measure long-term outcomes.
- Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to evaluate angiographic outcomes.
Expert Insights
Prof. Bernardo Cortese has shared his thoughts on the trial: "After 3 and a half years, we completed the enrollment in the TRANSFORM II trial involving 52 centers across three continents. This achievement reflects the dedicated efforts of our Team and Investigators, enabling swift enrollment in this ambitious study. Our goal is to advance the adoption of drug-coated balloons in cardiac interventions by testing sirolimus DCB against the most widely used DES in real-world patient populations. This effort aligns with recent DCB ARC guidelines and signals a new era for modern angioplasty!"
Transformative Treatment Potential
Coronary vessels of this size account for about 80% of patients undergoing percutaneous coronary interventions, presenting unique treatment challenges. Currently, the standard choice is a drug-eluting stent, which may limit long-term outcomes for patients. The TRANSFORM II trial aims to provide essential evidence comparing MagicTouch SCB with the existing standard care of the EES family of drug-eluting stents. This study has the potential to reshape treatment practices by offering an alternative approach to managing coronary artery disease.
Advancements in Drug-Coated Balloon Technology
Drug-coated balloon technology has emerged as a promising solution for managing small de-novo coronary lesions, featuring sirolimus as an advantageous option over the first-generation DCB that used paclitaxel. Data derived from this large-scale RCT is expected to support a pivotal shift towards wider adoption of drug-coated balloons in clinical practice. The careful analysis of outcomes will ultimately lead to beneficial insights into the long-term advantages of non-permanent implants in coronary vessels.
Commitment to Innovation
Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, expressed excitement regarding this milestone: "The completion of patient enrollment in TRANSFORM II marks a significant achievement in our ongoing commitment to enhance drug-delivery technologies within interventional cardiology. We take pride in supporting one of the largest global randomized trials focusing on sirolimus-coated balloon technology. This milestone demonstrates our dedication to clinical excellence and the pursuit of improved patient outcomes worldwide."
About MagicTouch SCB
The MagicTouch SCB, developed by Concept Medical Inc., employs advanced Nanoluté technology to ensure deep penetration of sirolimus into vessel walls with high precision. The device has received CE Mark approval, along with Breakthrough Device Designation and IDE Approval from the U.S. FDA, targeting small coronary vessels and in-stent restenosis with ongoing clinical trials.
About Concept Medical Inc.
Concept Medical Inc., based in Tampa, Florida, focuses on enhancing patient care through innovative research and development of drug-delivery technologies. Their platforms are designed to deliver pharmaceuticals with unmatched accuracy across vascular luminal surfaces. Concept Medical is recognized for developing the MagicTouch family of Sirolimus-Coated Balloons (SCB), which stand as the first and most utilized SCB technology globally. With applications treating both coronary and peripheral artery diseases, over a million patients have benefited from these advanced treatments.
Frequently Asked Questions
What is the main goal of the TRANSFORM II trial?
The main goal is to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon compared to the everolimus-eluting stent in treating de-novo coronary vessels.
How many patients were enrolled in this study?
The study achieved a target enrollment of over 1,820 patients.
What are the primary endpoints of the trial?
The primary endpoint focuses on assessing Target Lesion Failure at 12 months, utilizing a non-inferiority design.
What does the future hold for drug-coated balloons?
This trial aims to validate and potentially establish drug-coated balloons as a standard treatment option, making them a viable alternative to permanent implants.
Who leads the TRANSFORM II trial?
The trial is led by Prof. Bernardo Cortese, who chairs the study along with a distinguished steering committee.
